CHF1.40
2.03% yesterday
SIX Swiss Exchange, May 20, 05:30 pm CET
ISIN
CH0363463438
Symbol
IDIA
Sector
Industry

Idorsia Stock price

CHF1.40
+0.26 23.16% 1M
+0.68 94.33% 6M
+0.58 70.80% YTD
-0.82 36.76% 1Y
-13.77 90.74% 3Y
-29.00 95.38% 5Y
-12.25 89.71% 10Y
SIX Swiss Exchange, Closing price Tue, May 20 2025
+0.03 2.03%
ISIN
CH0363463438
Symbol
IDIA
Sector
Industry

Key metrics

Market capitalization CHF286.13m
Enterprise Value CHF1.47b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 9.34
P/S ratio (TTM) P/S ratio 1.81
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 11.61%
Revenue (TTM) Revenue CHF157.83m
EBIT (operating result TTM) EBIT CHF-261.72m
Free Cash Flow (TTM) Free Cash Flow CHF-321.08m
Cash position CHF64.85m
EPS (TTM) EPS CHF-1.28
P/E forward negative
P/S forward 1.87
EV/Sales forward 9.66
Show more

Is Idorsia a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Idorsia Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Idorsia forecast:

1x Hold
50%
1x Sell
50%

Analyst Opinions

2 Analysts have issued a Idorsia forecast:

Hold
50%
Sell
50%

Financial data from Idorsia

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
158 158
12% 12%
100%
- Direct Costs 51 51
81% 81%
32%
107 107
6% 6%
68%
- Selling and Administrative Expenses 229 229
26% 26%
145%
- Research and Development Expense 122 122
45% 45%
78%
-244 -244
42% 42%
-155%
- Depreciation and Amortization 18 18
4% 4%
11%
EBIT (Operating Income) EBIT -262 -262
41% 41%
-166%
Net Profit -217 -217
288% 288%
-137%

In millions CHF.

Don't miss a Thing! We will send you all news about Idorsia directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Idorsia Ltd. operates as a biopharmaceutical firm which focuses on discovery, development and commercialization of innovative medicines for unmet medical needs. The firm targets patients who are suffering with Fabry disease, insomnia, Cerebral vasospasm associated with aSAH and systemic lupus erythematosus. The was founded on March 3, 2017 and is headquartered in Allschwil, Switzerland.

Head office Switzerland
CEO André Muller
Founded 2017
Website www.idorsia.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today